Business Description
Ionis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US4622221004
Total Employee Number:
1,402Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.94 | |||||
Equity-to-Asset | 0.14 | |||||
Debt-to-Equity | 4.15 | |||||
Debt-to-EBITDA | -9.4 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 2.4 | |||||
Beneish M-Score | -1.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.5 | |||||
3-Year EBITDA Growth Rate | -2 | |||||
3-Year EPS without NRI Growth Rate | -0.9 | |||||
3-Year FCF Growth Rate | 0.7 | |||||
3-Year Book Growth Rate | -9.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 35.85 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
14-Day RSI | 80.56 | |||||
12-1 Month Momentum % | 77.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.1 | |||||
Quick Ratio | 4.09 | |||||
Cash Ratio | 2.68 | |||||
Days Inventory | 192.72 | |||||
Days Payable | 454.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -4.37 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.35 | |||||
Operating Margin % | -33.29 | |||||
Net Margin % | -30.9 | |||||
EBITDA Margin % | -20.52 | |||||
FCF Margin % | -88.78 | |||||
OCF Margin % | -82.53 | |||||
ROE % | -60.42 | |||||
ROA % | -10.34 | |||||
ROIC % | -31.52 | |||||
3-Year ROIIC % | 4.07 | |||||
ROC (Joel Greenblatt) % | -52.92 | |||||
ROCE % | -9.87 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 12.78 | |||||
PB Ratio | 26.77 | |||||
Price-to-Tangible-Book | 26.79 | |||||
EV-to-EBIT | -54.68 | |||||
EV-to-Forward-EBIT | 79.32 | |||||
EV-to-EBITDA | -60.91 | |||||
EV-to-Forward-EBITDA | 400.01 | |||||
EV-to-Revenue | 12.5 | |||||
EV-to-Forward-Revenue | 12.24 | |||||
EV-to-FCF | -13.53 | |||||
Price-to-GF-Value | 1.47 | |||||
Price-to-Median-PS-Value | 1.27 | |||||
Earnings Yield (Greenblatt) % | -1.83 | |||||
FCF Yield % | -7.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ionis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 19,541.476 | ||
| EPS (TTM) (MXN) | -36.9 | ||
| Beta | 1.1257 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.53 | ||
| Volatility % | 77.74 | ||
| 14-Day RSI | 80.56 | ||
| 14-Day ATR (MXN) | 0.000012 | ||
| 20-Day SMA (MXN) | 1150 | ||
| 12-1 Month Momentum % | 77.74 | ||
| 52-Week Range (MXN) | 647 - 1180 | ||
| Shares Outstanding (Mil) | 165.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ionis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ionis Pharmaceuticals Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-29 11:30 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 120 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 11:30 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 29 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 08:40 | 1,150.00 (+0.00%) | ||
| General meeting for 2026 | 2026-06-04 14:00 | 1,150.00 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-19 08:30 | 1,150.00 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-12 13:40 | 1,150.00 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 08:30 | 1,150.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 1,150.00 (+0.00%) |
Show
Entries
Ionis Pharmaceuticals Inc Frequently Asked Questions
What is Ionis Pharmaceuticals Inc(MEX:IONS)'s stock price today?
The current price of MEX:IONS is MXN1150.00. The 52 week high of MEX:IONS is MXN1180.00 and 52 week low is MXN647.00.
When is next earnings date of Ionis Pharmaceuticals Inc(MEX:IONS)?
The next earnings date of Ionis Pharmaceuticals Inc(MEX:IONS) is 2026-07-30 Est..
Does Ionis Pharmaceuticals Inc(MEX:IONS) pay dividends? If so, how much?
Ionis Pharmaceuticals Inc(MEX:IONS) does not pay dividend.
Press Release
Articles on Ionis Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers